It makes other people's molecules, so its revenue follows their launch calendars rather than its own effort. PI synthesises agrochemical active ingredients to order for the innovators who own the patents, and sells its own brands to Indian farmers. In the year to March 2026 that was ₹6,416 crore of ₹6,714 crore of revenue (consolidated), earning ₹1,369 crore. FY26 shows what the model does in a down year and what it protects. Export revenue fell 19% on 14% lower volumes, after three years of 26%, 19% and 5%. Yet gross margin rose 507 basis points to about 58% on the company's own measure, because five new molecules were commercialised and last-three-year molecules now make up 18% of export sales. Selling less of a better mix is the whole business in one line. What the mix could not offset was the volume: return on capital fell from 22.8% to 15.9%.
PI discloses the number that predicts the business and withholds the one that measures it. The predictor is molecule count. Five were commercialised in FY26, and products launched in the last three years make up 18% of AgChem export revenue — that ratio is the replacement rate, and it is why gross margin reached about 58% on the company's own measure (consolidated, FY26) in a year revenue fell 16%. The measure it withholds is capacity utilisation, and there is no figure anywhere in the annual report. The order book gets only "held steady". So a reader can see the pipeline refilling but cannot tell whether the plants running it are half empty — at a company committing ₹700–800 crore a year to more of them. Good disclosure on the hard part, silence on the easy one.
Debt free, and the year's cash went somewhere more interesting than lenders. At 31 March 2026 borrowings were ₹238 crore against ₹3,427 crore the company calls surplus net cash (consolidated). Debt to equity 0.03. Crisil reaffirmed AA+/Stable in July 2026, and PI has "consistently chosen financial flexibility over financial leverage". The strain is not on the balance sheet, it is inside it. Net working capital days went from 73 to 139 in one year, inventory days from 45 to 66, and operating cash flow fell from ₹1,413 crore to ₹474 crore. A debt-free company still had to fund that, and it did — from the pile. Management took 19 days back out in the June quarter, releasing ₹300 crore. That reversal, not the leverage ratio, is the number to follow.
A bad year that the five-year record says is a pause, and the June quarter says is not over. Revenue for the year to March 2026 was ₹6,714 crore (consolidated), down 15.9%. Profit after tax ₹1,321 crore, down 20.4%. EBITDA margin slipped from 27.7% to 25.8%. Over five years from FY21 revenue has still compounded at 8.0% and profit at 12.3% — this is one down year inside a rising line, not a broken business. But the June 2026 quarter was worse than the full year it followed: revenue ₹1,702 crore, down 10%, profit ₹244 crore, down 39%. Management expects recovery in the second half.
Profit has grown faster than revenue for five years, and in FY26 it fell faster too. Revenue compounded at 8.0% a year from FY21 and profit at 12.3% (consolidated) — the gap is margin, which went from 21.6% to a peak of 27.4% before this year. That works in both directions. FY26 revenue fell 15.9% and profit fell 20.4%, because the same operating leverage runs backwards. Three-year revenue growth is now 1.1% a year. The reason is not competitive. Global innovators deferred delivery schedules through an industry-wide destocking cycle, and PI's export volumes fell 14%.
The business that earns the money was built. The newest ones were bought. Agrochemicals — 96% of revenue — is organic, grown from a single plant in 1976 through capacity and chemistry rather than deals. What is new arrived by acquisition: Isagro's horticulture business in 2021, then PI Health Sciences assembled from purchases in the US, India and Italy including Archimica, and in FY26 Plant Health Care, now PI AgSciences, bringing PREtec peptide technology and registrations in five countries. The bought half is not yet paying. Pharma lost ₹48 crore in FY26 (consolidated segment note), and the biologicals business is spending on market development ahead of revenue. Share count has not moved since FY21. The buying was funded from cash, not from shareholders.
Gross margin improved and operating margin fell, which tells you where the money went. Gross margin rose about 507 basis points to roughly 58% in the year to March 2026, on the company's own measure (consolidated) — the mix genuinely got better as new molecules replaced old ones. Below that line, EBITDA margin fell from 27.7% to 25.8%, because overheads rose 8% on 16% less revenue. The company spent into a downturn: commercial teams for biologicals, capability for pharma. The chief executive's own framing is worth quoting — "you may call it good losses, which is equated to investing". Whether it is depends on revenue arriving that has not yet arrived.
The weakest return on capital in nine years, and not all of it is the cycle. Return on capital employed was 15.9% for the year to March 2026 (consolidated), against 22.8%. Return on equity 11.8% against 16.4%. The previous low across the series was 17.3% in FY22. Profit falling 20.4% explains most of it. The rest is capital sitting in the base without earning: ₹1,030 crore of construction in progress inside ₹11,573 crore of capital employed, and subsidiaries that are still loss-making — the pharma segment lost ₹48 crore in FY26.
Profit turned into cash at a third of its usual rate, and working capital is the whole reason. Operating cash flow was ₹474 crore in the year to March 2026 (consolidated) against ₹1,413 crore — on profit of ₹1,321 crore, a conversion of 0.36 times. Over three years it averages 0.84. Net working capital went from 73 days to 139 in twelve months. Inventory days rose from 45 to 66 as PI held stock ahead of expected demand that did not come, and receivables ran at 88 days. The June quarter took 19 days back and released ₹300 crore, so the correction has started.
A founder family in its second generation, with a professional chairman and a board that lost an executive during the year. Mayank Singhal is Vice Chairperson and Managing Director, his tenure running to September 2030. Salil Singhal, of the founding generation, is Chairperson Emeritus. Narayan K Seshadri, a chartered accountant and former KPMG India managing partner, chairs the board as a non-executive but non-independent director. Sanjay Agarwal is Group Chief Financial Officer and Shruti Joshi Company Secretary. At 31 March 2026 the board was ten: two executive, eight non-executive, of whom four were independent. That is 40% independent under a non-independent chair. The change since is Rajnish Sarna, who resigned as Joint Managing Director on 19 May 2026 after three decades and stays on as a non-executive director.
Clean, and the one penalty on record is two years old. Price Waterhouse Chartered Accountants LLP has audited PI since its reappointment at the 2022 annual meeting, with the term running to the 2027 meeting. The report carries no qualification, reservation or adverse remark, standalone or consolidated. Contingent liabilities are ₹140 crore (consolidated) at 31 March 2026, of which ₹95 crore is disputed income tax — about 1% of net worth, and unremarkable for the size. On environment, PI recorded one violation of legal obligations in FY24, with a ₹50 lakh penalty. FY25 and FY26 both show zero fines and zero violations. Nothing here argues with the numbers elsewhere on this page.
It sells trust with someone else's patent, which is a harder thing to win than a price. An innovator handing PI a molecule is handing over a compound still under patent, to be made at scale, to specification, without leaking to anyone else. That relationship is why five molecules were commercialised in FY26 in a year customers were cutting orders. No other agrochemical contract manufacturer is covered on this site, so the honest comparison set is the seven specialty chemicals companies here — and PI is the only one whose revenue is set by other companies' product launches. Its domestic half is the opposite business: own brands, own pricing. In the June quarter management chose volume over price, and said so, while peers were taking the price.
Third largest of the seven specialty chemicals companies covered here, and much the cheapest of them. Revenue of ₹6,714 crore in FY26 sits behind SRF at ₹15,787 crore and Deepak Nitrite at ₹7,887 crore, ahead of Gujarat Fluorochemicals at ₹4,996 crore and Navin Fluorine at ₹3,314 crore. On earnings PI trades at 28.3 times, against SRF at 41.7, Deepak at 44.0, Navin at 66.1, Acutaas at 74.9, Gujarat Fluorochemicals at 92.6 and Aether at 100.1. It is the only one of the seven below thirty times. On return on capital it ranks third at 15.9%, behind Acutaas at 32.3% and Navin at 21.2%. Cheapest, and third best on returns. The market is pricing the direction of travel, not the position.
In its favour: a rule change in China, and a pipeline that keeps refilling. From April 2026 China withdraws VAT rebates on certain pesticide technicals and intermediates, which the company expects to temper aggressive export pricing. India is already the second largest agrochemical exporter behind China, and progress on an India-EU trade agreement points the same way. Underneath that, molecules commercialised in the last three years are 18% of export revenue, and gross margin rose 507 basis points in a year revenue fell 16%. Against it: PI does not decide when its own revenue arrives. Global innovators deferred delivery schedules through FY26, export volumes fell 14%, and the same phasing hit the pharma order book in the June quarter. The domestic half depends on weather, crop prices and channel inventory — all three went the wrong way. And the businesses meant to be the next leg, biologicals and pharma, are still loss-making: pharma lost ₹48 crore in FY26.
The tide is structural. The revenue is not, and PI's arrives on a schedule someone else sets. Global crop protection has been through a prolonged inventory correction — innovators, distributors, retailers and growers all destocking at once, worsened by Middle East disruption in the March 2026 quarter and a shift to just-in-time buying. What makes PI's own line uneven is narrower than the cycle: it manufactures patented molecules for a handful of innovators, and a customer moving a launch or a delivery by one quarter moves PI's revenue with it. Management says so plainly about pharma — order books get delayed, "but eventually they come if you are locked in with a customer". That is the trade. Contracted revenue with almost no price risk, and almost no control over timing.
The cheapest of the seven specialty chemicals companies here, on the worst year it has had in a decade. At ₹2,467 on 27 August 2026 PI was worth ₹37,424 crore: 28.3 times the year to March 2026's earnings, 3.3 times book, 5.6 times sales. Every other company in that set trades above forty times. The bull case is that the denominator is depressed and the balance sheet is not: ₹3,427 crore of net cash is 9% of the market value, and China's VAT change lands in FY27. The bear case is management's own guidance of "lower single digit" growth, and a June quarter worse than the year before it.
Twenty-eight times earnings — the only one of its peer group under thirty, and near the market's own average. On 27 August 2026 the share was ₹2,467: 28.3 times earnings of ₹87.06, 3.3 times book and 5.6 times sales, with an earnings yield of 3.5%. Most Indian companies trade between 20 and 30 times, so this is one of the few specialty chemicals names priced like the market rather than above it. Against the others covered here — SRF at 41.7, Deepak Nitrite at 44.0, Navin Fluorine at 66.1, Acutaas at 74.9, Gujarat Fluorochemicals at 92.6, Aether at 100.1 — PI is cheapest by a distance. No growth-adjusted multiple is shown: profit fell 20.4% this year, and dividing a multiple by a negative growth rate produces a number that looks like information and is not.
Foreign funds sold, retail sold, and Indian mutual funds bought all of it. Foreign institutions fell in every one of the six quarters filed, from 18.05% in March 2025 to 14.83% at 30 June 2026. Domestic institutions rose in every one, 27.57% to 31.64%, with mutual funds alone going from 16.92% to 22.31%. The unusual part is retail. The number of shareholders fell 6.3% over the year, from 150,401 to 140,999, and the public holding fell from 7.58% to 7.44% — individuals leaving a share that dropped a third, which is the opposite of what usually happens on a fall. Promoters did not move a share.
Seven holders above 1%, and three of them are index funds that did not choose PI at all. At 30 June 2026: ICICI Prudential Manufacturing Fund 7.61%, LICI New Pension Plus Growth Fund 7.01%, a Kotak Nifty index fund 2.58%, SBI Arbitrage Opportunities Fund 2.24%, Mirae Asset Nifty LargeMidcap 250 Index Fund 1.97%, Axis Mutual Fund 1.90% and Tata Nifty Midcap 150 Index Fund 1.04%. Three index trackers and an arbitrage fund come to 7.8% held for reasons unconnected to the business. The list turned over almost completely from March 2025, when Life Insurance Corporation led it at 6.37%. Read that carefully — fund houses relabel schemes, and both ICICI Prudential and LIC appear on the old list and the new under different names.
A dividend it kept, no buyback, and one share issue in the company's modern history. PI paid ₹15 per share for FY26 — ₹5 interim and ₹10 final on a ₹1 face value — a payout of 17.3% of consolidated profit. The dividend was maintained in a year profit fell a fifth. There has been no buyback and no bonus. The only equity raised was ₹2,000 crore through an institutional placement in the September 2020 quarter at ₹1,470 a share, fully spent — ₹1,842 crore into subsidiaries and ₹133 crore on plant. Share count has been 151,718,118 since FY21, so five-year dilution is zero. Those placement buyers are 68% up six years later, which is less than it sounds.
Loading…